The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone
- PMID: 17340127
- DOI: 10.1007/s00210-007-0146-x
The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone
Abstract
This study characterized the pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, its metabolite, ADL 08-0011, and methylnaltrexone. The activities of the compounds were investigated with respect to human or guinea pig opioid receptor binding and function in recombinant cell lines and mechanical responsiveness of the guinea pig ileum. Alvimopan and ADL 08-0011 had higher binding affinity than methylnaltrexone at human mu opioid receptors (pK (i) values of 9.6, 9.6, and 8.0, respectively). The compounds had different selectivities for the mu receptor over human delta and guinea pig kappa opioid receptors. ADL 08-0011 had the highest mu receptor selectivity. With respect to their mu opioid receptor functional activity ([(35)S]GTPgammaS incorporation), methylnaltrexone had a positive intrinsic activity, consistent with partial agonism, unlike alvimopan and ADL 08-0011, which had negative intrinsic activities. Alvimopan, ADL 08-0011, and methylnaltrexone antagonized inhibitory responses mediated by the mu opioid agonist, endomorphin-1 (pA (2) values of 9.6, 9.4, and 7.6, respectively) and by U69593, a kappa opioid agonist (pA (2) values of 8.4, 7.2, and 6.7, respectively). In morphine-naive guinea pig ileum, methylnaltrexone reduced, while alvimopan and ADL 08-0011 increased, the amplitude of electrically evoked contractions and spontaneous mechanical activity. In tissue from morphine-dependent animals, alvimopan and ADL 08-0011 increased spontaneous activity to a greater degree than methylnaltrexone. The data suggested that alvimopan-induced contractions resulted predominantly from an interaction with kappa opioid receptors. It is concluded that alvimopan, ADL 08-0011, and methylnaltrexone differ in their in vitro pharmacological properties, particularly with respect to opioid receptor subtype selectivity and intrinsic activity. The clinical significance of the data from this study remains to be determined.
Similar articles
-
The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91. doi: 10.1007/s00210-013-0850-7. Epub 2013 Apr 4. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23549670
-
SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.Brain Res Bull. 2001 Jul 1;55(4):507-11. doi: 10.1016/s0361-9230(01)00550-0. Brain Res Bull. 2001. PMID: 11543951
-
Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.J Med Chem. 1998 Jul 16;41(15):2872-81. doi: 10.1021/jm980083i. J Med Chem. 1998. PMID: 9667975
-
Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.Neurogastroenterol Motil. 2018 May;30(5):e13250. doi: 10.1111/nmo.13250. Epub 2017 Nov 9. Neurogastroenterol Motil. 2018. PMID: 29119706 Review.
-
Opioid receptors in the gastrointestinal tract.Regul Pept. 2009 Jun 5;155(1-3):11-7. doi: 10.1016/j.regpep.2009.03.012. Epub 2009 Apr 2. Regul Pept. 2009. PMID: 19345246 Free PMC article. Review.
Cited by
-
Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.ACS Med Chem Lett. 2019 Nov 26;10(12):1641-1647. doi: 10.1021/acsmedchemlett.9b00406. eCollection 2019 Dec 12. ACS Med Chem Lett. 2019. PMID: 31857840 Free PMC article.
-
The Pharmacokinetics of Subcutaneous Methylnaltrexone Bromide in Rhesus Macaques (Macaca mulatta).J Am Assoc Lab Anim Sci. 2023 May 1;62(3):260-266. doi: 10.30802/AALAS-JAALAS-22-000111. Epub 2023 Apr 20. J Am Assoc Lab Anim Sci. 2023. PMID: 37080736 Free PMC article.
-
New approaches to the treatment of opioid-induced constipation.Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1(0 1):119-27. Eur Rev Med Pharmacol Sci. 2008. PMID: 18924451 Free PMC article. Review.
-
Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Ther Clin Risk Manag. 2010 Mar 3;6:77-82. doi: 10.2147/tcrm.s4301. Ther Clin Risk Manag. 2010. PMID: 20234787 Free PMC article.
-
The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91. doi: 10.1007/s00210-013-0850-7. Epub 2013 Apr 4. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23549670
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials